Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Fierce Biotech: For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot…June 22, 2023
Anumana Joins Accelerating Medicines Partnership Heart Failure Program to Advance ECG-AI® Research
Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditionsOctober 24, 2024
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023
Anumana Names Dr. Simos Kedikoglou President & COO
AI Tech 365: Anumana, a leading AI-driven health technology company, announced the appointment of Dr. Simos Kedikoglou as President and Chief Operating Officer (COO), effective immediately.January 10, 2025